NCT03479229 - Viveve Geneveve Treatment of the Vaginal Introitus to Evaluate Safety and Efficacy | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

April 20, 2018

Primary Completion Date

March 15, 2020

Study Completion Date

March 15, 2020

Conditions

Female Sexual Dysfunction

Interventions

DEVICE

Geneveve Treatment

The active treatment group will receive a treatment dose of 90 J/cm\^2

DEVICE

Sham Treatment

The sham group will receive a sub-therapeutic dose of ≤ 1 J/cm\^2.

Trial Locations (21)

10038

VIVEVE II Study Site, New York

20036

VIVEVE II Study Site, Washington D.C.

27612

VIVEVE II Study Site, Raleigh

30342

VIVEVE II Study Site, Atlanta

33324

VIVEVE II Study Site, Plantation

33409

VIVEVE II Study Site, West Palm Beach

33461

VIVEVE II Study Site, Lake Worth

38305

VIVEVE II Study Site, Jackson

43221

VIVEVE II Study Site, Columbus

49009

VIVEVE II Study Site, Kalamazoo

63117

VIVEVE II Study Site, St Louis

68114

VIVEVE II Study Site, Omaha

80209

VIVEVE II Study Site, Denver

83404

VIVEVE II Study Site, Idaho Falls

87131

VIVEVE II Study Site, Albuquerque

91942

VIVEVE II Study Site, La Mesa

92868

VIVEVE II Study Site, Orange

98042

VIVEVE II Study Site, Tacoma

08901

VIVEVE II Study Site, New Brunswick

T2J 6A5

VIVEVE II Study Site, Calgary

A1B 3V6

VIVEVE II Study Site, St. Johns

All Listed Sponsors

lead

Viveve Inc.

INDUSTRY